Pathway-based personalized analysis of cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages 6388-6393

  Drier, Yotam ^a,b   Sheffer, Michal ^a   Domany, Eytan ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; EPIDERMAL GROWTH FACTOR RECEPTOR;

ALGORITHM; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DEREGULATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; OXIDATIVE PHOSPHORYLATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

ALGORITHMS; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; RECEPTORS, CXCR3; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SOFTWARE; SYSTEMS BIOLOGY;

EID: 84876261160     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219651110     Document Type: Article

References (40)

1. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52): 21276-21281.
2. Thomas DC, et al.; American Association for Cancer Research (2008) Approaches to complex pathways in molecular epidemiology: Summary of a special conference of the American Association for Cancer Research. Cancer Res 68(24):10028-10030.
3. Segal E, Friedman N, Koller D, Regev A (2004) A module map showing conditional activity of expression modules in cancer. Nat Genet 36(10):1090-1098.
4. Bild AH, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074):353-357.
5. Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534-555.
6. Doniger SW, et al. (2003) MAPPFinder: Using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 4(1):R7.
7. Cary MP, Bader GD, Sander C (2005) Pathway information for systems biology. FEBS Lett 579(8):1815-1820.
8. Efroni S, Schaefer CF, Buetow KH (2007) Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS ONE 2(5):e425.
9. Thomas DC, et al. (2009) Use of pathway information in molecular epidemiology. Hum Genomics 4(1):21-42.
10. Emmert-Streib F, Glazko GV (2011) Pathway analysis of expression data: deciphering functional building blocks of complex diseases. PLOS Comput Biol 7(5):e1002053.
11. Vaske CJ, et al. (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26(12):i237-i245.
12. Kanehisa M, Goto S (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28(1):27-30.
13. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 40(Database issue): D109-D114.
14. Nishimura D (2001) BioCarta. Biotech Software Internet Report 2(3):117-120.
15. Schaefer CF, et al. (2009) PID: The Pathway Interaction Database. Nucleic Acids Res 37(Database issue):D674-D679.
16. Hastie T, Stuetzle W (1989) Principal curves. J Am Stat Assoc 84(406):502-516.
17. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
18. Lee JC, et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3(12):e485.
19. Madhavan S, et al. (2009) Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7(2):157-167.
20. Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157-173.
21. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated ge-nomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110.
22. Mawrin C, et al. (2003) Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol 23(3):641-648.
23. Mason WP, et al. (2012) A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol 107(2): 343-349.
24. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424-430.
25. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2):172-187.
26. Andersson U, et al. (2004) Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol 108(2):135-142.
27. Dong Y, et al. (2011) Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Int J Oncol 38(2):555-569.
28. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9-22.
29. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396(6712):643-649.
30. Sheffer M, et al. (2009) Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer. Proc Natl Acad Sci USA 106(17):7131-7136.
31. Sveen A, et al. (2011) Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med 3(5):32.
32. Kogo R, et al. (2011) Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 71(20):6320-6326.
33. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carci-nogenesis. Nature 363(6429):558-561.
34. Smyrk TC, Watson P, Kaul K, Lynch HT (2001) Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91(12): 2417-2422.
35. Na KY, Bacchini P, Bertoni F, Kim YW, Park YK (2012) Syndecan-4 and fibronectin in osteosarcoma. Pathology 44(4):325-330.
36. Lacotte S, Brun S, Muller S, Dumortier H (2009) CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173:310-317.
37. Razis E, et al. (2012) Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer 12(3): 183-193.
38. Ein-Dor L, Kela I, Getz G, Givol D, Domany E (2005) Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 21(2):171-178.
39. Drier Y, Domany E (2011) Do two machine-learning based prognostic signatures for breast cancer capture the same biological processes? PLoS ONE 6(3):e17795.
40. Simon R (2008) Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 44(18):2707-2713.